Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report

MLA

Gong J, et al. “Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report.” Clinical, Cosmetic and Investigational Dermatology, vol. ume 15, Dec. 2022, pp. 2949–56. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.75192b41a28e4e65b508ace27cd605b3&authtype=sso&custid=ns315887.

APA

Gong J, Wu W, Qiu L, Wang X, Bao J, Wang J, Cheng L, Fu Z, & Hu F. (2022). Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report. Clinical, Cosmetic and Investigational Dermatology, ume 15, 2949–2956.

Chicago

Gong J, Wu W, Qiu L, Wang X, Bao J, Wang J, Cheng L, Fu Z, and Hu F. 2022. “Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report.” Clinical, Cosmetic and Investigational Dermatology ume 15 (December): 2949–56. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.75192b41a28e4e65b508ace27cd605b3&authtype=sso&custid=ns315887.